Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Disposition of levobupivacaine during intraoperative continuous caudal epidural analgesia in a preterm neonate

J. Sipek, P. Pokorna, M. Sima, J. Styblova, V. Mixa

. 2024 ; 168 (1) : 81-84. [pub] 20231122

Jazyk angličtina Země Česko

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005429

BACKGROUND: Continuous caudal epidural analgesia used intraoperatively in children is an effective and safe technique. However, in preterm neonates, developmental factors may significantly affect levobupivacaine disposition, leading to variable pharmacokinetics, pharmacodynamics, and potential large-variable systemic toxicity of local anesthetics. OBJECTIVE: To our knowledge, this is the first case report describing the disposition of levobupivacaine used for intraoperative caudal epidural analgesia in a preterm neonate treated for the postoperative pain profile. METHOD: 4-days old neonate (postmenstrual age 35+5, weight 2140 g) with congenital anal atresia received continuous caudal epidural long-term analgesia (loading dose 1.694 mg/kg, initial infusion 0.34 mg/kg/hour) before correction surgery. The blood samples were obtained at 1.0, 1.5, 6.5, 12, and 36.5 h after the start of epidural infusion. The pharmacokinetic profile of levobupivacaine was determined by using the Stochastic Approximation Expectation Maximization algorithm. COMFORT and NIPS pain scores were used for the assessment of epidural analgesia. RESULTS: The levobupivacaine absorption rate constant, apparent volume of distribution, apparent clearance, and elimination half-life were 10.8 h-1, 0.9 L, 0.086 L/h, and 7.3 h, respectively. CONCLUSION: The results confirm our hypothesis of altered pharmacokinetics in the preterm neonate. Therefore, levobupivacaine therapy in these patients should be carefully monitored. Since therapeutic drug monitoring of levobupivacaine is not established in clinical routines, we suggest monitoring the intraoperative pain profile using validated scores. TRIAL REGISTRATION: EudraCT number: 2020-000595-37.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005429
003      
CZ-PrNML
005      
20250403105215.0
007      
ta
008      
240404s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.047 $2 doi
035    __
$a (PubMed)37997373
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Šípek, Jan $u Department of Anaesthesia, Resuscitation and Intensive Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital Motol, Prague, Czech Republic $7 xx0222931
245    10
$a Disposition of levobupivacaine during intraoperative continuous caudal epidural analgesia in a preterm neonate / $c J. Sipek, P. Pokorna, M. Sima, J. Styblova, V. Mixa
520    9_
$a BACKGROUND: Continuous caudal epidural analgesia used intraoperatively in children is an effective and safe technique. However, in preterm neonates, developmental factors may significantly affect levobupivacaine disposition, leading to variable pharmacokinetics, pharmacodynamics, and potential large-variable systemic toxicity of local anesthetics. OBJECTIVE: To our knowledge, this is the first case report describing the disposition of levobupivacaine used for intraoperative caudal epidural analgesia in a preterm neonate treated for the postoperative pain profile. METHOD: 4-days old neonate (postmenstrual age 35+5, weight 2140 g) with congenital anal atresia received continuous caudal epidural long-term analgesia (loading dose 1.694 mg/kg, initial infusion 0.34 mg/kg/hour) before correction surgery. The blood samples were obtained at 1.0, 1.5, 6.5, 12, and 36.5 h after the start of epidural infusion. The pharmacokinetic profile of levobupivacaine was determined by using the Stochastic Approximation Expectation Maximization algorithm. COMFORT and NIPS pain scores were used for the assessment of epidural analgesia. RESULTS: The levobupivacaine absorption rate constant, apparent volume of distribution, apparent clearance, and elimination half-life were 10.8 h-1, 0.9 L, 0.086 L/h, and 7.3 h, respectively. CONCLUSION: The results confirm our hypothesis of altered pharmacokinetics in the preterm neonate. Therefore, levobupivacaine therapy in these patients should be carefully monitored. Since therapeutic drug monitoring of levobupivacaine is not established in clinical routines, we suggest monitoring the intraoperative pain profile using validated scores. TRIAL REGISTRATION: EudraCT number: 2020-000595-37.
650    _2
$a dítě $7 D002648
650    _2
$a novorozenec $7 D007231
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a levobupivakain $x terapeutické užití $7 D000077554
650    12
$a bupivakain $7 D002045
650    12
$a epidurální analgezie $x škodlivé účinky $x metody $7 D015360
650    _2
$a anestetika lokální $7 D000779
650    _2
$a pooperační bolest $x farmakoterapie $x etiologie $7 D010149
650    _2
$a dvojitá slepá metoda $7 D004311
655    _2
$a kazuistiky $7 D002363
700    1_
$a Pokorná, Pavla $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $u Department of Physiology and Pharmacology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden $7 xx0122705
700    1_
$a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0222901
700    1_
$a Stýblová, Jitka $u Department of Paediatric Surgery, 2nd Faculty of Medicine, Charles University and Faculty Hospital Motol, Prague, Czech Republic $7 xx0106038
700    1_
$a Mixa, Vladimír $u Department of Anaesthesia, Resuscitation and Intensive Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital Motol, Prague, Czech Republic $7 xx0134681
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 1 (2024), s. 81-84
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37997373 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20240404 $b ABA008
991    __
$a 20250403105210 $b ABA008
999    __
$a ok $b bmc $g 2295212 $s 1215189
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 1 $d 81-84 $e 20231122 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK116 $a Pubmed-20240404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...